ProQR Therapeutics
PRQR
70 hedge funds and large institutions have $113M invested in ProQR Therapeutics in 2026 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 11 reducing their positions, and 11 closing their positions.
127% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 11
99% more capital invested
Capital invested by funds: $56.8M → $113M (+$56.1M)
24.35% more ownership
Funds ownership: 33.3% → 57.65% (+24%)
1% more funds holding
Funds holding: 69 → 70 (+1)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$9.25M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$5.4M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$5.09M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.55M |
| 5 |
HCM
Heights Capital Management
San Francisco,
California
|
+$4.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$3.17M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.16M |
| 3 |
Walleye Capital
New York
|
-$984K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$472K |
| 5 |
MAM
Monaco Asset Management
Monaco
|
-$287K |
PRQR Hedge Fund Activity: Q2 2026 in Review
70 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q2 2026, worth a combined $113M — up 99% from $56.8M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PRQR positions and 11 closed out — a net gain of 1 holder — while 25 added to existing stakes and 11 trimmed.
The largest buyer was Aberdeen Group, adding an estimated $9.25M. The largest seller was Sio Capital Management, exiting entirely with an estimated $3.17M sold.
- 70 institutional investors held ProQR Therapeutics (PRQR) as of Q2 2026, up from 69 in Q1 2026.
- Funds reported $113M of ProQR Therapeutics stock for Q2 2026, up 99% quarter-over-quarter.
- 12 funds opened new ProQR Therapeutics positions in Q2 2026 and 11 closed out, a net change of +1 holder.
- The largest ProQR Therapeutics buyer in Q2 2026 was Aberdeen Group, an estimated $9.25M added.
- The largest ProQR Therapeutics seller in Q2 2026 was Sio Capital Management, an estimated $3.17M sold.
Based on aggregated 13F filings for Q2 2026.